当前位置: X-MOL 学术J. Med. Chem. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Fragment-Based Drug Discovery of Potent Protein Kinase C Iota Inhibitors
Journal of Medicinal Chemistry ( IF 7.3 ) Pub Date : 2018-04-24 00:00:00 , DOI: 10.1021/acs.jmedchem.8b00060
Jacek Kwiatkowski 1 , Boping Liu 1 , Doris Hui Ying Tee 1 , Guoying Chen 1 , Nur Huda Binte Ahmad 1 , Yun Xuan Wong 1 , Zhi Ying Poh 1 , Shi Hua Ang 1 , Eldwin Sum Wai Tan 1 , Esther HQ Ong 1 , Nurul Dinie 1 , Anders Poulsen 1 , Vishal Pendharkar 1 , Kanda Sangthongpitag 1 , May Ann Lee 1 , Sugunavathi Sepramaniam 1 , Soo Yei Ho 1 , Joseph Cherian 1 , Jeffrey Hill 1 , Thomas H. Keller 1 , Alvin W. Hung 1
Affiliation  

Protein kinase C iota (PKC-ι) is an atypical kinase implicated in the promotion of different cancer types. A biochemical screen of a fragment library has identified several hits from which an azaindole-based scaffold was chosen for optimization. Driven by a structure–activity relationship and supported by molecular modeling, a weakly bound fragment was systematically grown into a potent and selective inhibitor against PKC-ι.

中文翻译:

蛋白质激酶C Iota抑制剂的基于片段的药物发现

蛋白激酶C iota(PKC-1)是一种非典型激酶,与促进不同类型的癌症有关。片段文库的生化筛选已鉴定出多个命中,从中选择了基于氮杂吲哚的支架进行优化。在结构-活性关系的驱动下,并在分子模型的支持下,弱结合的片段被系统地生长为有效且选择性的针对PKC-1的抑制剂。
更新日期:2018-04-24
down
wechat
bug